公开(公告)号：US08673941B2

公开(公告)日：2014-03-18

申请号：US13057415

申请日：2009-07-30

申请人： Harry Chobanian ,  Linus S. Lin ,  Ping Liu ,  Marc D. Chioda ,  Robert J. DeVita ,  Ravi P. Nargund ,  Yan Guo

发明人： Harry Chobanian ,  Linus S. Lin ,  Ping Liu ,  Marc D. Chioda ,  Robert J. DeVita ,  Ravi P. Nargund ,  Yan Guo

IPC分类号： A01N43/40 ,  A61K31/44

CPC分类号： C07D413/14 ,  C07D263/46 ,  C07D271/06 ,  C07D271/10 ,  C07D413/04 ,  C07D413/10 ,  C07D417/04 ,  C07D417/14

摘要： The present invention is directed to certain oxazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer Disease, and Parkinson's Disease.

摘要翻译： 本发明涉及可用作脂肪酸酰胺水解酶（FAAH）抑制剂的某些恶唑衍生物。 本发明还涉及包含这些化合物作为活性成分的药物制剂，以及这些化合物及其制剂在治疗某些疾病，包括骨关节炎，类风湿性关节炎，糖尿病性神经病变，带状疱疹后神经痛，ke肉肌痛和纤维肌痛等方面的用途。 作为急性疼痛，偏头痛，睡眠障碍，阿尔茨海默病和帕金森病。

公开(公告)号：US20120115894A1

公开(公告)日：2012-05-10

申请号：US13254363

申请日：2010-02-22

申请人： Ping Liu ,  Robert J. DeVita ,  Linus S. Lin ,  Marc D. Chioda ,  Terence G Hamill ,  Wenping Li

发明人： Ping Liu ,  Robert J. DeVita ,  Linus S. Lin ,  Marc D. Chioda ,  Terence G Hamill ,  Wenping Li

IPC分类号： A61K31/506 ,  A61K31/4439 ,  C07D233/84 ,  A61K31/4164 ,  C07D413/14 ,  C07D401/14 ,  C07D413/10 ,  A61K31/4245 ,  A61P19/02 ,  A61P29/00 ,  A61P25/00 ,  A61P25/06 ,  A61P25/20 ,  A61P25/28 ,  A61P25/16 ,  C07D401/12

CPC分类号： C07D401/12 ,  C07D401/14 ,  C07D413/10 ,  C07D413/14

摘要： The present invention is directed to certain Inidazole derivatives which are useful as modulators of Fatty Acid Amide Hydrolase (FAAH) and as FAAH imaging agents. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.

摘要翻译： 本发明涉及可用作脂肪酸酰胺水解酶（FAAH）和FAAH显像剂的调节剂的某些咪唑衍生物。 本发明还涉及包含这些化合物作为活性成分的药物制剂，以及这些化合物及其制剂在治疗某些疾病，包括骨关节炎，类风湿性关节炎，糖尿病性神经病变，带状疱疹后神经痛，ke肉肌痛和纤维肌痛等方面的用途。 作为急性疼痛，偏头痛，睡眠障碍，阿尔茨海默病和帕金森病。

公开(公告)号：US20110269769A1

公开(公告)日：2011-11-03

申请号：US12996429

申请日：2009-06-04

申请人： Linus S. Lin ,  Marc D. Chioda ,  Ping Liu ,  Ravi P. Nargund

发明人： Linus S. Lin ,  Marc D. Chioda ,  Ping Liu ,  Ravi P. Nargund

IPC分类号： A61K31/501 ,  C07D417/04 ,  C07D401/04 ,  C07D403/04 ,  C07D405/14 ,  C07D405/04 ,  C07D413/14 ,  C07D401/14 ,  A61K31/4164 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/4178 ,  A61K31/444 ,  A61K31/513 ,  A61P25/28 ,  A61P25/16 ,  A61P19/08 ,  A61P19/02 ,  A61P25/02 ,  A61P25/00 ,  A61P29/00 ,  A61P25/06 ,  C07D233/84

CPC分类号： A61K31/4174 ,  A61K31/4178 ,  C07D233/84 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D409/04 ,  C07D413/04 ,  C07D413/10 ,  C07D413/14 ,  C07D417/04 ,  C07D471/14

摘要： The present invention is directed to certain imidazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.

摘要翻译： 本发明涉及可用作脂肪酸酰胺水解酶（FAAH）抑制剂的某些咪唑衍生物。 本发明还涉及包含这些化合物作为活性成分的药物制剂，以及这些化合物及其制剂在治疗某些障碍（包括骨关节炎，类风湿性关节炎，糖尿病性神经病变，带状疱疹后神经痛，ke肉肌痛和纤维肌痛）中的用途以及 作为急性疼痛，偏头痛，睡眠障碍，阿尔茨海默病和帕金森病。

公开(公告)号：US20110021531A1

公开(公告)日：2011-01-27

申请号：US12509542

申请日：2009-07-27

申请人： Harry CHOBANIAN ,  Linus S. Lin ,  Ping Liu ,  Marc D. Chioda ,  Robert J. DeVita ,  Ravi P. Nargund ,  Yan Guo

发明人： Harry CHOBANIAN ,  Linus S. Lin ,  Ping Liu ,  Marc D. Chioda ,  Robert J. DeVita ,  Ravi P. Nargund ,  Yan Guo

IPC分类号： A61K31/497 ,  C07D413/14 ,  A61K31/444 ,  A61K31/501 ,  A61P25/00 ,  A61P19/00

CPC分类号： A61K31/444 ,  A61K31/497 ,  A61K31/501 ,  C07D413/14

摘要： The present invention is directed to certain oxazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer Disease, and Parkinson's Disease.

摘要翻译： 本发明涉及可用作脂肪酸酰胺水解酶（FAAH）抑制剂的某些恶唑衍生物。 本发明还涉及包含这些化合物作为活性成分的药物制剂，以及这些化合物及其制剂在治疗某些疾病，包括骨关节炎，类风湿性关节炎，糖尿病性神经病变，带状疱疹后神经痛，ke肉肌痛和纤维肌痛等方面的用途。 作为急性疼痛，偏头痛，睡眠障碍，阿尔茨海默病和帕金森病。

公开(公告)号：US20110144119A1

公开(公告)日：2011-06-16

申请号：US13057415

申请日：2009-07-30

申请人： Harry Chobanian ,  Linus S. Lin ,  Ping Liu ,  Marc D. Chioda ,  Robert J. DeVita ,  Ravi P. Nargund ,  Yan Guo

发明人： Harry Chobanian ,  Linus S. Lin ,  Ping Liu ,  Marc D. Chioda ,  Robert J. DeVita ,  Ravi P. Nargund ,  Yan Guo

IPC分类号： A61K31/501 ,  C07D413/14 ,  A61K31/497 ,  C07D413/04 ,  A61K31/444 ,  A61K31/4439 ,  A61K31/506 ,  C07D263/46 ,  A61K31/421 ,  C07D413/10 ,  A61K31/4245 ,  C07D413/12 ,  A61K31/4545 ,  C07D417/14 ,  A61K31/4725 ,  A61K31/4709 ,  A61P19/02 ,  A61P29/00 ,  A61P25/00 ,  A61P25/04 ,  A61P25/06 ,  A61P25/20 ,  A61P25/28 ,  A61P25/16

CPC分类号： C07D413/14 ,  C07D263/46 ,  C07D271/06 ,  C07D271/10 ,  C07D413/04 ,  C07D413/10 ,  C07D417/04 ,  C07D417/14

摘要： The present invention is directed to certain oxazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.

摘要翻译： 本发明涉及可用作脂肪酸酰胺水解酶（FAAH）抑制剂的某些恶唑衍生物。 本发明还涉及包含这些化合物作为活性成分的药物制剂，以及这些化合物及其制剂在治疗某些疾病，包括骨关节炎，类风湿性关节炎，糖尿病性神经病变，带状疱疹后神经痛，ke肉肌痛和纤维肌痛等方面的用途。 作为急性疼痛，偏头痛，睡眠障碍，阿尔茨海默病和帕金森病。

公开(公告)号：US08455528B2

公开(公告)日：2013-06-04

申请号：US12996429

申请日：2009-06-04

申请人： Linus S. Lin ,  Marc D. Chioda ,  Ping Liu ,  Ravi P. Nargund

发明人： Linus S. Lin ,  Marc D. Chioda ,  Ping Liu ,  Ravi P. Nargund

IPC分类号： A61K31/4174 ,  A61K31/4178 ,  C07D233/84

CPC分类号： A61K31/4174 ,  A61K31/4178 ,  C07D233/84 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D409/04 ,  C07D413/04 ,  C07D413/10 ,  C07D413/14 ,  C07D417/04 ,  C07D471/14

摘要： The present invention is directed to certain imidazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.

摘要翻译： 本发明涉及可用作脂肪酸酰胺水解酶（FAAH）抑制剂的某些咪唑衍生物。 本发明还涉及包含这些化合物作为活性成分的药物制剂，以及这些化合物及其制剂在治疗某些疾病，包括骨关节炎，类风湿性关节炎，糖尿病性神经病变，带状疱疹后神经痛，ke肉肌痛和纤维肌痛等方面的用途。 作为急性疼痛，偏头痛，睡眠障碍，阿尔茨海默病和帕金森病。

公开(公告)号：US08664253B2

公开(公告)日：2014-03-04

申请号：US13254363

申请日：2010-02-22

申请人： Ping Liu ,  Robert J. DeVita ,  Linus S. Lin ,  Marc D. Chioda ,  Terence G. Hamill ,  Wenping Li

发明人： Ping Liu ,  Robert J. DeVita ,  Linus S. Lin ,  Marc D. Chioda ,  Terence G. Hamill ,  Wenping Li

IPC分类号： A61K31/4178 ,  A61K31/4439 ,  C07D401/10

CPC分类号： C07D401/12 ,  C07D401/14 ,  C07D413/10 ,  C07D413/14

摘要： The present invention is directed to certain Inidazole derivatives which are useful as modulators of Fatty Acid Amide Hydrolase (FAAH) and as FAAH imaging agents. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.

摘要翻译： 本发明涉及可用作脂肪酸酰胺水解酶（FAAH）和FAAH显像剂的调节剂的某些咪唑衍生物。 本发明还涉及包含这些化合物作为活性成分的药物制剂，以及这些化合物及其制剂在治疗某些疾病，包括骨关节炎，类风湿性关节炎，糖尿病性神经病变，带状疱疹后神经痛，ke肉肌痛和纤维肌痛等方面的用途。 作为急性疼痛，偏头痛，睡眠障碍，阿尔茨海默病和帕金森病。

公开(公告)号：US20050234061A1

公开(公告)日：2005-10-20

申请号：US11109076

申请日：2005-04-19

申请人： William Hagmann ,  Linus Lin ,  Shrenik Shah ,  Ravindra Guthikonda ,  Hongbo Qi ,  Linda Chang ,  Ping Liu ,  Helen Armstrong ,  James Jewell ,  Thomas Lanza

发明人： William Hagmann ,  Linus Lin ,  Shrenik Shah ,  Ravindra Guthikonda ,  Hongbo Qi ,  Linda Chang ,  Ping Liu ,  Helen Armstrong ,  James Jewell ,  Thomas Lanza

IPC分类号： A61K31/165 ,  A61K31/27 ,  A61K31/40 ,  A61K31/4015 ,  A61K31/403 ,  A61K31/405 ,  A61K31/415 ,  A61K31/4192 ,  A61K31/4196 ,  A61K31/42 ,  A61K31/423 ,  A61K31/426 ,  A61K31/428 ,  A61K31/437 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4409 ,  A61K31/4436 ,  A61K31/445 ,  A61K31/4453 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/50 ,  A61K31/501 ,  A61K31/505 ,  A61K31/5377 ,  A61K31/553 ,  A61P1/04 ,  A61P1/10 ,  A61P1/16 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61P5/24 ,  A61P9/04 ,  A61P9/06 ,  A61P9/10 ,  A61P9/12 ,  A61P9/14 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P15/10 ,  A61P17/00 ,  A61P19/02 ,  A61P19/06 ,  A61P25/00 ,  A61P25/06 ,  A61P25/08 ,  A61P25/16 ,  A61P25/18 ,  C07C233/12 ,  C07C233/13 ,  C07C235/06 ,  C07C235/18 ,  C07C235/20 ,  C07C235/34 ,  C07C235/74 ,  C07C235/78 ,  C07C237/06 ,  C07C255/55 ,  C07C255/60 ,  C07C271/14 ,  C07C271/22 ,  C07C275/30 ,  C07C311/03 ,  C07C323/41 ,  C07D207/27 ,  C07D209/08 ,  C07D209/34 ,  C07D209/52 ,  C07D209/94 ,  C07D211/34 ,  C07D213/36 ,  C07D213/40 ,  C07D213/56 ,  C07D213/61 ,  C07D213/64 ,  C07D213/65 ,  C07D213/68 ,  C07D213/89 ,  C07D215/06 ,  C07D231/12 ,  C07D233/36 ,  C07D233/70 ,  C07D233/80 ,  C07D237/14 ,  C07D237/28 ,  C07D237/32 ,  C07D239/34 ,  C07D249/04 ,  C07D249/08 ,  C07D249/12 ,  C07D249/18 ,  C07D261/08 ,  C07D261/20 ,  C07D263/58 ,  C07D267/14 ,  C07D277/20 ,  C07D277/30 ,  C07D277/36 ,  C07D277/64 ,  C07D277/74 ,  C07D295/12 ,  C07D295/13 ,  C07D295/14 ,  C07D295/15 ,  C07D401/12 ,  C07D409/12 ,  C07D413/12 ,  C07D471/04 ,  C07D513/04 ,  C07D521/00 ,  A61K31/502 ,  A61K31/401

CPC分类号： C07D213/64 ,  C07C233/13 ,  C07C235/06 ,  C07C235/20 ,  C07C235/34 ,  C07C235/74 ,  C07C235/78 ,  C07C237/06 ,  C07C255/55 ,  C07C255/60 ,  C07C271/14 ,  C07C271/22 ,  C07C275/30 ,  C07C311/03 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2602/08 ,  C07D209/34 ,  C07D209/94 ,  C07D211/34 ,  C07D213/65 ,  C07D213/68 ,  C07D215/06 ,  C07D231/12 ,  C07D233/56 ,  C07D233/70 ,  C07D237/28 ,  C07D237/32 ,  C07D239/34 ,  C07D249/04 ,  C07D249/08 ,  C07D249/12 ,  C07D263/58 ,  C07D267/14 ,  C07D277/30 ,  C07D277/36 ,  C07D295/13 ,  C07D295/15 ,  C07D513/04

摘要： Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

公开(公告)号：US11944384B2

公开(公告)日：2024-04-02

申请号：US16969817

申请日：2019-01-29

申请人： Xuemin Xu ,  Aili Zhang ,  Jianqi Sun ,  Ping Liu ,  Jingfeng Bai

发明人： Xuemin Xu ,  Aili Zhang ,  Jianqi Sun ,  Ping Liu ,  Wentao Li

IPC分类号： A61B34/10 ,  A61B18/00 ,  A61B18/02 ,  A61B18/14

CPC分类号： A61B34/10 ,  A61B18/02 ,  A61B2018/00041 ,  A61B2018/00404 ,  A61B2018/00577 ,  A61B2018/00791 ,  A61B2018/00863 ,  A61B2018/00988 ,  A61B2018/0293 ,  A61B18/1477 ,  A61B2034/104 ,  A61B2034/105 ,  A61B2034/107

摘要： The present application relates to computer-based preoperative planning technology, and discloses a preoperative planning method for multimodal ablation treatment and apparatus thereof, which can automatically provide objective, scientific, and quantitative multimodal ablation planning information. In this method, acquiring parameters of an volume to be ablated; calculating property changes of the tissue caused by performing freezing on the volume according to the parameters of the volume to be ablated, and acquiring a first planning data required for the property changes of the tissue to satisfy a first predetermined condition; further calculating property changes of the tissue caused by performing heating on the volume to acquire a second planning data required for the property changes of the tissue to satisfy a second predetermined condition based on the properties satisfying the first predetermined condition; outputting the first planning data and the second planning data.

公开(公告)号：US20170158698A1

公开(公告)日：2017-06-08

申请号：US15128782

申请日：2015-03-23

申请人： Helen MITCHELL ,  Mark E. FRALEY ,  Andrew J. COOKE ,  Craig A. STUMP ,  Xu-Fang ZHANG ,  Casey C. MCCOMAS ,  Kathy SCHIRRIPA ,  Melody MCWHERTER ,  Ping LIU ,  Dann PARKER ,  Chun Sing LI ,  Qinghua MAO ,  Merck Sharp & Dohme Corp.

发明人： Helen Mitchell ,  Mark E. Fraley ,  Andrew J. Cooke ,  Craig A. Stump ,  Xu-Fang Zhang ,  Casey C. McComas ,  Kathy Schirripa ,  Melody McWherter ,  Ping Liu ,  Dann Parker ,  Chun Sing Li ,  Qinghua Mao

IPC分类号： C07D487/04 ,  C07D231/40 ,  C07D417/12 ,  C07D401/04 ,  C07D417/14 ,  C07D471/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D413/12 ,  C07D413/14 ,  C07D277/46 ,  C07D403/14

CPC分类号： C07D487/04 ,  C07D231/40 ,  C07D277/46 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D403/12 ,  C07D403/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04

摘要： The present invention is directed to substituted five membered heteroaryl benzamide compounds of formula (I) (Formula (I)) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.